<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997980</url>
  </required_header>
  <id_info>
    <org_study_id>IRCCSPSM 1</org_study_id>
    <nct_id>NCT04997980</nct_id>
  </id_info>
  <brief_title>AMSA and Amiodarone Study in Cardiac Arrest</brief_title>
  <acronym>MOSAIC</acronym>
  <official_title>aMsa and amiOdarone Study in cArdiaC Arrest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of the Basque Country (UPV/EHU)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators' aim is to assess whether the administration of amiodarone during resuscitation&#xD;
      could cause a reduction of the values of the amplitude spectral area (AMSA).&#xD;
&#xD;
      Amiodarone is recommended for the treatment of cardiac arrest due to ventricular&#xD;
      tachycardia/ventricular fibrillation (VT/VF) ( with a low level of recommendation cause of&#xD;
      conflicting results. AMSA is a parameter expressing the amplitude of VF and it has been shown&#xD;
      to predict defibrillation success and the return of spontaneous circulation (ROSC). No data&#xD;
      are available so far about the impact of amiodarone administration on AMSA values.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study endpoint of the present study is to determine whether patients who received&#xD;
      amiodarone during advanced resuscitation had lower values of AMSA as compared to those who&#xD;
      did not receive amiodarone.&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
      The secondary endpoints of this study are:&#xD;
&#xD;
        1. To assess, after correction for confounders, the rate of successful defibrillation, the&#xD;
           rate of ROSC and the rate of short-term survival (survived event or survival to hospital&#xD;
           discharge according to the available data) both in the amiodarone and non-amiodarone&#xD;
           group.&#xD;
&#xD;
        2. To assess the role of AMSA for shock success and ROSC prediction in amiodarone group and&#xD;
           in non-amiodarone group.&#xD;
&#xD;
      Type of study. This is a multicentre study based on a retrospective analysis of&#xD;
      prospectically collected data.&#xD;
&#xD;
      Study population All the out-of-hospital cardiac arrests (OHCA) which occurred from January&#xD;
      1st, 2015 to December 31st, 2020 will be considered for the present study. In the analysis&#xD;
      the investigators will include only those patients who received at least one shock for&#xD;
      ventricular fibrillation during advanced resuscitation regardless whether or not the&#xD;
      presenting rhythm was shockable or non-shockable.&#xD;
&#xD;
      The study cohort will involve cases retrieved from the Lombardia CARe registry (Lombardia&#xD;
      Cardiac Arrest Registry NCT03197142), from the registry of Oslo and Vestfold&#xD;
&#xD;
      Data Collection Data from different databases will be integrated and combined in a single ad&#xD;
      hoc database for statistical analysis.&#xD;
&#xD;
      For every shock, both pre-shock carbon dioxide at the end ot the tidal volume (ETCO2) and&#xD;
      pre-shock AMSA will be calculated. The median ETCO2 value in the minute before the shock&#xD;
      (METCO2) will be computed automatically either from a capnogram, when available, applying the&#xD;
      algorithm described by Aramendi et al, or from the defibrillator with a ETCO2 monitoring&#xD;
      feature. AMSA will be computed using a 2-second-pre-shock ECG interval, free of chest&#xD;
      compression artifacts, leaving a 1-second guard before the shock. The electrocardiogram (ECG)&#xD;
      will be bandpass filtered (0.5-30Hz) and the fast Fourier transform computed to obtain AMSA&#xD;
      in the 2-48 Hz bandwidth.&#xD;
&#xD;
      For each patient all the pre-hospital variables will be included according to the 2014&#xD;
      Utstein recommendations and the number of shocks will be computed. The mean value of both&#xD;
      ETCO2 and of AMSA will be calculated.&#xD;
&#xD;
      Statistical analysis Categorical variables will be compared with the Chi-square test and&#xD;
      presented as number and percentage. Continuous variables will be compared with the t-test and&#xD;
      presented as mean ± standard deviation, or compared with the Mann-Whitney test and presented&#xD;
      as median and interquartile range (IQR) according to normal distribution tested with the&#xD;
      D'Agostino-Pearson test. A multivariable regression model will be fitted both for shock&#xD;
      success and for ROSC (including all non-correlated potential predictors) and to test the&#xD;
      effect of amiodarone on AMSA values after correction for confounders.&#xD;
&#xD;
      The values of AMSA in the amiodarone and in the non-amiodarone group will then be compared in&#xD;
      two groups of shocks randomly matched and identified via propensity score matching, so that&#xD;
      they are homogeneous for time to shock, pre-shock ETCO2, outcome of defibrillation and the&#xD;
      age of the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AMSA values</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>to determine whether AMSA values in the Amiodarone group are lower than in the NO Amiodarone gorup</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful defibrilaltion</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>to assess the rate of successful defibrillation in the Amiodarone and in the NO Amiodarone group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ROSC</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>to assess the rate of ROSC in the Amiodarone and in the NO Amiodarone group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survived event</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>to assess the rate of &quot;survived event&quot; in the Amiodarone and in the NO Amiodarone group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival to hospital discharge</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>to assess the rate of survival to hospital discharge in the Amiodarone and in the NO Amiodarone group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prediction</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>to verify if AMSA maintain its predictive role for defibrillation success and ROSC also in the Amiodarone group</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Out-Of-Hospital Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Amiodarone group</arm_group_label>
    <description>Patients who did receive amiodarone during the attempt of resuscitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO Amiodarone</arm_group_label>
    <description>Patients who did receive amiodarone during the attempt of resuscitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone Injection</intervention_name>
    <arm_group_label>Amiodarone group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All the consecutive patients suffering of out-of-hospital cardiac arrest with a shockable&#xD;
        presenting rhythm and receiving an advanced attempt of resuscitation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        clinical:&#xD;
&#xD;
          -  patients with out-of-hospital cardiac arrest&#xD;
&#xD;
          -  shockable presenting rhythm&#xD;
&#xD;
          -  resuscitation attempted&#xD;
&#xD;
          -  advanced resuscitation attempted&#xD;
&#xD;
        technical: - VF cardiac arrest (and not VT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        clinical:&#xD;
&#xD;
          -  non-shockable presenting rhythm&#xD;
&#xD;
          -  resuscitation not attempted&#xD;
&#xD;
        technical:&#xD;
&#xD;
        - AMSA not evaluable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Savastano, MD</last_name>
      <phone>+390382501590</phone>
      <email>s.savastano@smatteo.pv.it</email>
    </contact>
    <contact_backup>
      <last_name>Francesca Romana Gentile, MD</last_name>
      <phone>+390382501590</phone>
      <email>francescaromanagentile49@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Francesca Romana Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enrico Baldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Compagnoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessia Currao, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Bendotti, MSD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Primi, MSD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0010</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Wik, MD</last_name>
      <email>lars.wik@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Lars Wik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestfold Hospital trust</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorn Evert Jacobsen, MD</last_name>
      <email>joejac@siv.no</email>
    </contact>
    <investigator>
      <last_name>Jorn Evert Jacobsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioRes Research Group</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Schwartz PJ, Zaza A. The Sicilian Gambit revisited--theory and practice. Eur Heart J. 1992 Nov;13 Suppl F:23-9. Review.</citation>
    <PMID>1478220</PMID>
  </reference>
  <reference>
    <citation>Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 1984 Apr;3(4):1059-71. Review.</citation>
    <PMID>6368644</PMID>
  </reference>
  <reference>
    <citation>Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. Pacing Clin Electrophysiol. 1988 Jan;11(1):7-12. Review.</citation>
    <PMID>2449675</PMID>
  </reference>
  <reference>
    <citation>Zhou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol. 1998 Jun;31(7):1672-8.</citation>
    <PMID>9626850</PMID>
  </reference>
  <reference>
    <citation>Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006 Jul 11;114(2):104-9. Epub 2006 Jul 3.</citation>
    <PMID>16818810</PMID>
  </reference>
  <reference>
    <citation>Jung W, Manz M, Pizzulli L, Pfeiffer D, Lüderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992 Oct 15;70(11):1023-7.</citation>
    <PMID>1414899</PMID>
  </reference>
  <reference>
    <citation>Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987 Jul;114(1 Pt 1):8-17.</citation>
    <PMID>3604876</PMID>
  </reference>
  <reference>
    <citation>Soar J, Berg KM, Andersen LW, Böttiger BW, Cacciola S, Callaway CW, Couper K, Cronberg T, D'Arrigo S, Deakin CD, Donnino MW, Drennan IR, Granfeldt A, Hoedemaekers CWE, Holmberg MJ, Hsu CH, Kamps M, Musiol S, Nation KJ, Neumar RW, Nicholson T, O'Neil BJ, Otto Q, de Paiva EF, Parr MJA, Reynolds JC, Sandroni C, Scholefield BR, Skrifvars MB, Wang TL, Wetsch WA, Yeung J, Morley PT, Morrison LJ, Welsford M, Hazinski MF, Nolan JP; Adult Advanced Life Support Collaborators. Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Resuscitation. 2020 Nov;156:A80-A119. doi: 10.1016/j.resuscitation.2020.09.012. Epub 2020 Oct 21.</citation>
    <PMID>33099419</PMID>
  </reference>
  <reference>
    <citation>Sanfilippo F, Corredor C, Santonocito C, Panarello G, Arcadipane A, Ristagno G, Pellis T. Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2016 Oct;107:31-7. doi: 10.1016/j.resuscitation.2016.07.235. Epub 2016 Aug 3. Review.</citation>
    <PMID>27496262</PMID>
  </reference>
  <reference>
    <citation>Tagami T, Yasunaga H, Yokota H. Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Crit Care. 2017 Mar 21;21(1):59. doi: 10.1186/s13054-017-1639-8. Review.</citation>
    <PMID>28320450</PMID>
  </reference>
  <reference>
    <citation>Tagami T, Matsui H, Tanaka C, Kaneko J, Kuno M, Ishinokami S, Unemoto K, Fushimi K, Yasunaga H. Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. Cardiovasc Drugs Ther. 2016 Oct;30(5):485-491.</citation>
    <PMID>27618826</PMID>
  </reference>
  <reference>
    <citation>Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in Cardiac Arrest: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018 Mar;27(3):280-290. doi: 10.1016/j.hlc.2017.07.004. Epub 2017 Aug 23. Review.</citation>
    <PMID>28988724</PMID>
  </reference>
  <reference>
    <citation>Zhao H, Fan K, Feng G. Amiodarone and/or lidocaine for cardiac arrest: A Bayesian network meta-analysis. Am J Emerg Med. 2020 Oct;38(10):2185-2193. doi: 10.1016/j.ajem.2020.06.074. Epub 2020 Jul 5.</citation>
    <PMID>33071078</PMID>
  </reference>
  <reference>
    <citation>Ong ME, Pellis T, Link MS. The use of antiarrhythmic drugs for adult cardiac arrest: a systematic review. Resuscitation. 2011 Jun;82(6):665-70. doi: 10.1016/j.resuscitation.2011.02.033. Epub 2011 Mar 27. Review.</citation>
    <PMID>21444143</PMID>
  </reference>
  <reference>
    <citation>Kudenchuk PJ, Leroux BG, Daya M, Rea T, Vaillancourt C, Morrison LJ, Callaway CW, Christenson J, Ornato JP, Dunford JV, Wittwer L, Weisfeldt ML, Aufderheide TP, Vilke GM, Idris AH, Stiell IG, Colella MR, Kayea T, Egan D, Desvigne-Nickens P, Gray P, Gray R, Straight R, Dorian P; Resuscitation Outcomes Consortium Investigators. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017 Nov 28;136(22):2119-2131. doi: 10.1161/CIRCULATIONAHA.117.028624. Epub 2017 Sep 13.</citation>
    <PMID>28904070</PMID>
  </reference>
  <reference>
    <citation>Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999 Sep 16;341(12):871-8.</citation>
    <PMID>10486418</PMID>
  </reference>
  <reference>
    <citation>Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002 Mar 21;346(12):884-90. Erratum in: N Engl J Med 2002 Sep 19;347(12):955.</citation>
    <PMID>11907287</PMID>
  </reference>
  <reference>
    <citation>Ristagno G, Li Y, Fumagalli F, Finzi A, Quan W. Amplitude spectrum area to guide resuscitation-a retrospective analysis during out-of-hospital cardiopulmonary resuscitation in 609 patients with ventricular fibrillation cardiac arrest. Resuscitation. 2013 Dec;84(12):1697-703. doi: 10.1016/j.resuscitation.2013.08.017. Epub 2013 Sep 1.</citation>
    <PMID>24005007</PMID>
  </reference>
  <reference>
    <citation>Ristagno G, Mauri T, Cesana G, Li Y, Finzi A, Fumagalli F, Rossi G, Grieco N, Migliori M, Andreassi A, Latini R, Fornari C, Pesenti A; Azienda Regionale Emergenza Urgenza Research Group. Amplitude spectrum area to guide defibrillation: a validation on 1617 patients with ventricular fibrillation. Circulation. 2015 Feb 3;131(5):478-87. doi: 10.1161/CIRCULATIONAHA.114.010989. Epub 2014 Dec 2. Erratum in: Circulation. 2015 May 19;131(20):e502.</citation>
    <PMID>25466976</PMID>
  </reference>
  <reference>
    <citation>Salcido DD, Schmicker RH, Kime N, Buick JE, Cheskes S, Grunau B, Zellner S, Zive D, Aufderheide TP, Koller AC, Herren H, Nuttall J, Sundermann ML, Menegazzi JJ; Resuscitation Outcomes Consortium Investigators. Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial. Resuscitation. 2018 Aug;129:6-12. doi: 10.1016/j.resuscitation.2018.05.028. Epub 2018 May 24.</citation>
    <PMID>29803703</PMID>
  </reference>
  <reference>
    <citation>Frigerio L, Baldi E, Aramendi E, Chicote B, Irusta U, Contri E, Palo A, Compagnoni S, Fracchia R, Iotti G, Oltrona Visconti L, Savastano S; Lombardia CARe Researchers. End-tidal carbon dioxide (ETCO(2)) and ventricular fibrillation amplitude spectral area (AMSA) for shock outcome prediction in out-of-hospital cardiac arrest. Are they two sides of the same coin? Resuscitation. 2021 Mar;160:142-149. doi: 10.1016/j.resuscitation.2020.10.032. Epub 2020 Nov 10.</citation>
    <PMID>33181229</PMID>
  </reference>
  <reference>
    <citation>Ristagno G, Gullo A, Berlot G, Lucangelo U, Geheb E, Bisera J. Prediction of successful defibrillation in human victims of out-of-hospital cardiac arrest: a retrospective electrocardiographic analysis. Anaesth Intensive Care. 2008 Jan;36(1):46-50.</citation>
    <PMID>18326131</PMID>
  </reference>
  <reference>
    <citation>Aiello S, Perez M, Cogan C, Baetiong A, Miller SA, Radhakrishnan J, Kaufman CL, Gazmuri RJ. Real-Time Ventricular Fibrillation Amplitude-Spectral Area Analysis to Guide Timing of Shock Delivery Improves Defibrillation Efficacy During Cardiopulmonary Resuscitation in Swine. J Am Heart Assoc. 2017 Nov 4;6(11). pii: e006749. doi: 10.1161/JAHA.117.006749.</citation>
    <PMID>29102980</PMID>
  </reference>
  <reference>
    <citation>Hulleman M, Salcido DD, Menegazzi JJ, Souverein PC, Tan HL, Blom MT, Koster RW. Predictive value of amplitude spectrum area of ventricular fibrillation waveform in patients with acute or previous myocardial infarction in out-of-hospital cardiac arrest. Resuscitation. 2017 Nov;120:125-131. doi: 10.1016/j.resuscitation.2017.08.219. Epub 2017 Aug 24.</citation>
    <PMID>28844935</PMID>
  </reference>
  <reference>
    <citation>Ruggeri L, Semeraro F, Ristagno G. Amplitude spectrum area: The &quot;clairvoyance&quot; during resuscitation in the era of predictive medicine. Resuscitation. 2017 Nov;120:A5-A6. doi: 10.1016/j.resuscitation.2017.09.011. Epub 2017 Sep 18.</citation>
    <PMID>28928017</PMID>
  </reference>
  <reference>
    <citation>Hulleman M, Salcido DD, Menegazzi JJ, Souverein PC, Tan HL, Blom MT, Koster RW. Ventricular fibrillation waveform characteristics in out-of-hospital cardiac arrest and cardiovascular medication use. Resuscitation. 2020 Jun;151:173-180. doi: 10.1016/j.resuscitation.2020.02.027. Epub 2020 Mar 10.</citation>
    <PMID>32169604</PMID>
  </reference>
  <reference>
    <citation>Aramendi E, Elola A, Alonso E, Irusta U, Daya M, Russell JK, Hubner P, Sterz F. Feasibility of the capnogram to monitor ventilation rate during cardiopulmonary resuscitation. Resuscitation. 2017 Jan;110:162-168. doi: 10.1016/j.resuscitation.2016.08.033. Epub 2016 Sep 23.</citation>
    <PMID>27670357</PMID>
  </reference>
  <reference>
    <citation>Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov;31(11):1061-9. Review.</citation>
    <PMID>1753010</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Simone Savastano</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>AMSA</keyword>
  <keyword>amiodarone</keyword>
  <keyword>Out-Of-Hospital Cardiac Arrest</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data could be shared under motivated request following a proposal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

